In this issue of Clinical Infectious Diseases,
Vazquez et al. [1] demonstrate in a wellconceived and well-conducted multicenter trial that posaconazole is equivalent in efficacy to fluconazole in the treatment of oropharyngeal candidiasis in HIV-infected patients. Patients given posaconazole also experienced fewer clinical relapses of oropharyngeal candidiasis than did patients given fluconazole. Does this mean that physicians should prescribe posaconazole to treat oropharyngeal candidiasis once the drug is approved by the US Food and Drug Administration? Or, more generally, what is the perspective from which a clinician should evaluate these results?
Oropharyngeal candidiasis is the current term used to describe disease of the linings of the oral cavity caused almost always by Candida albicans. Disease caused by Candida species, including oropharyngeal candidiasis, encompasses a broad spectrum, from the trivial to the most life-threatening of infections. Because the fungus is believed to reside in low numbers on mucous membranes in the healthy host, disease is attributable to a reduction in host defenses, and the host response depends in great measure on where lesions arise. For example, in the most common presentation of oropharyngeal candidiasis, pseudomembranous candidiasis (the type studied by Vazquez and colleagues), Gram staining of the curd-like lesions on buccal membranes demonstrates a tangle of oral bacteria, proliferating fungus (predominately blastoconidia and pseudohyphae), and polymorphonuclear leukocytes in an eosinophilic background. Other forms of oropharyngeal candidiasis manifest as glossitis or erythema in the fissures of the mouth or beneath denture plates.
Because the HIV pandemic is raging worldwide, oropharyngeal candidiasis must be reckoned as one of the most common diseases among humans. It is a sensitive and specific indicator of diminished numbers of CD4 + cells and heralds the onset of significant immune deficiency in people with HIV. For example, 128% of the first 500 patients visiting an HIV clinic in Ho Chi Minh City, Vietnam, had oropharyngeal candidiasis at the first or second visit, and 21% had pulmonary tuberculosis (with a median CD4 + cell count of 73 cells/mL for all patients) (unpublished data). Moreover, relapse of oropharyngeal candidiasis in patients undergoing HAART is a reliable indicator of drug noncompliance and, hence, worsening immune function. Table 1 lists the range of drugs for treatment of oropharyngeal candidiasis when the objective of treatment is to eliminate signs and symptoms of the disease and to prevent recurrences [2] . Fluconazole is rightfully the standard with which all other antifungal drugs should be compared for efficacy, lack of toxicity, ease of administration, and cost in the treatment of candidiasis. Since the advent of HAART in late 1995, the incidence of clinically refractory thrush (including that caused by azole-resistant strains) has decreased precipitously. Although this is undoubtedly because of the reconstitution of CD4 + cells by HAART, it is interesting to note that in vitro HIV-1 protease inhibitors inhibit the activity of Candida-secreted aspartyl proteinases, which likely contribute to disease on mucous membranes. Fluconazole administered at high doses (400-800 mg/ day) is used for the treatment of coccidioidomycosis in HIV-infected patients with no or few adverse effects, even among patients undergoing HAART. In some regions, such as in sub-Saharan Africa, where the incidence of cryptococcosis is high among HIV-infected patients, use of fluconazole may be cost-effective as prophylaxis against oropharyngeal candidiasis as well as cryptococcosis [3] . Fluconazole, metronidazole, and ceftriaxone remain "workhorse" antimicrobial drugs that are highly cost-effective and without equal with respect to the low incidences of adverse effects associated with them.
Posaconazole's niche in the antifungal armamentarium will be determined over time and with clinical use. Because of posaconazole's in vitro activity against Can- Effective but have significant "bidirectional" interactions through the cytochrome P-450 enzyme system with HAART and antitubercular drugs Fluconazole (oral, rectal, intravenous)
Highly effective and inexpensive; few adverse effects; given once per day; drug interactions through cytochrome P-450 enzyme system with HAART are not a problem Posaconazole Effective; given once per day; cytochrome P-450 interactions are projected to be minor but not known at present dida species other than C. albicans, Aspergillus species, Scedosporium species, and some Zygomycetes, it is likely that the drug will be used in the treatment of diseases caused by these fungi. As to whether posaconazole will prove useful in the treatment of or prophylaxis against oropharyngeal candidiasis, it seems that a subset of patients, such as those with bone marrow transplants who are at risk for filamentous fungal infections and non-C. albicans infections, would constitute a good trial cohort. Perhaps posaconazole will be found to have some unanticipated salutary effects as well. Ketoconazole, for example, possesses anti-inflammatory properties and activity against gram-positive cocci, properties that have been exploited in the treatment of seborrheic dermatitis.
In addition, its interference with sterol synthesis has led to its use as a secondary agent in the treatment of hormonerefractory prostate cancer. Itraconazole is often used to treat transplant recipients in the early months after surgery, because of its ability to inhibit cytochrome P-3A4 and, thus, raise blood levels of cyclosporine and tacrolimusa cost-sparing maneuver. It will be interesting to follow the introduction of posaconazole, other azoles, and new echinocandin drugs in the treatment of candidiasis. In the future, however, treatment of oropharyngeal candidiasis may evolve to include the use of other agents, such as topical antifungal peptides and/or probiotics, and these treatments may prove to be every bit as effective as current therapies.
